NFE2L2 and cancer: Mining publicly available single-cell RNA-sequencing (scRNA-seq) data in NSCLC reveals a wide distribution of NFE2L2 and G6PD (a key downstream effector of NRF2) 45, 47 expression across cancer cells, as well as diverse immune cell types, particularly within the myeloid lineage (Figure 4).